Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + pertuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1811 + pertuzumab is a combination of an investigational third-generation HER2-directed antibody-drug conjugate (ADC), SHR-A1811, and pertuzumab, a recombinant humanized monoclonal antibody targeting the HER2 protein. SHR-A1811 consists of an anti-HER2 antibody conjugated to a cytotoxic payload, designed for targeted delivery to HER2-overexpressing tumor cells, resulting in direct cytotoxicity to cancer cells. Pertuzumab binds to the extracellular dimerization domain (subdomain II) of HER2, inhibiting HER2 dimerization and downstream signaling that promotes cell growth and survival. This combination aims to improve clinical outcomes in patients with HER2-positive breast cancer, primarily as neoadjuvant therapy. Clinical development focuses on locally advanced or early-stage HER2-positive breast cancer, as assessed in phase II trials[1][2][3][5].
- Brand names
- Perjeta
- Other names
- SHR-A1811 + Perjeta
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SHR-A1811 + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + pertuzumab.